

Pleiotropic Analysis of Cancer Risk Loci on Esophageal Adenocarcinoma Risk

Eunjung Lee¹, Daniel O. Stram¹, Weronica E. Ek², Lynn E. Onstad³, Stuart MacGregor², Puya Gharakhani², Weimin Ye⁴, Jesper Lagergren^{5,6}, Nicholas J. Shaheen⁷, Liam J. Murray⁸, Laura J. Hardie⁹, Marilie D. Gammon¹⁰, Wong-Ho Chow¹¹, Harvey A. Risch¹², Douglas A. Corley^{13,14}, David M. Levine¹⁵, David C. Whiteman¹⁶, Leslie Bernstein¹⁷, Nigel C. Bird¹⁸, Thomas L. Vaughan³, and Anna H. Wu¹

Abstract

Background: Several cancer-associated loci identified from genome-wide association studies (GWAS) have been associated with risks of multiple cancer sites, suggesting pleiotropic effects. We investigated whether GWAS-identified risk variants for other common cancers are associated with risk of esophageal adenocarcinoma (EA) or its precursor, Barrett's esophagus.

Methods: We examined the associations between risks of EA and Barrett's esophagus and 387 SNPs that have been associated with risks of other cancers, by using genotype imputation data on 2,163 control participants and 3,885 (1,501 EA and 2,384 Barrett's esophagus) case patients from the Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study, and investigated

effect modification by smoking history, body mass index (BMI), and reflux/heartburn.

Results: After correcting for multiple testing, none of the tested 387 SNPs were statistically significantly associated with risk of EA or Barrett's esophagus. No evidence of effect modification by smoking, BMI, or reflux/heartburn was observed.

Conclusions: Genetic risk variants for common cancers identified from GWAS appear not to be associated with risks of EA or Barrett's esophagus.

Impact: To our knowledge, this is the first investigation of pleiotropic genetic associations with risks of EA and Barrett's esophagus. *Cancer Epidemiol Biomarkers Prev* 24(11); 1801–3. ©2015 AACR.

¹Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. ²Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ³Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. ⁴Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁵Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ⁶Division of Cancer Studies, King's College London, London, United Kingdom. ⁷Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, University of North Carolina, Chapel Hill, North Carolina. ⁸Centre for Public Health, Queen's University Belfast, United Kingdom. ⁹Division of Epidemiology, University of Leeds, Leeds, United Kingdom. ¹⁰Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina. ¹¹Department of Epidemiology, MD Anderson Cancer Center, Houston, Texas. ¹²Yale School of Public Health, Department of Chronic Disease Epidemiology, New Haven, Connecticut. ¹³Division of Research, Kaiser Permanente Northern California, Oakland, California. ¹⁴San Francisco Medical Center, Kaiser Permanente Northern California, San Francisco, California. ¹⁵Department of Biostatistics, University of Washington School of Public Health, Seattle, Washington. ¹⁶Cancer Control, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ¹⁷Department of Population Sciences, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, California. ¹⁸Department of Oncology, University of Sheffield Medical School, Sheffield, United Kingdom.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org/>).

Corresponding Author: Eunjung Lee, University of Southern California, 1441 Eastlake Ave., Norris Cancer Center NTT 4417A, Los Angeles, CA 90089. Phone: 323-865-0827; Fax: 323-865-0827; E-mail: leee@usc.edu

doi: 10.1158/1055-9965.EPI-15-0596

©2015 American Association for Cancer Research.

Introduction

The incidence of esophageal adenocarcinoma (EA) has increased substantially over the past four decades in western countries (1). Most EA arises within Barrett's esophagus, a metaplastic transformation of the lower esophageal lining (1). Gastroesophageal reflux (GERD), high body mass index (BMI), and tobacco use are well-established risk factors for both EA and Barrett's esophagus, although with some variations in the magnitudes of these associations. These risk factors, together with low consumption of fruits and vegetables, may explain about 70% of the EA cases (see references in ref. 1). Genetic factors are thought to play an etiologic role based on familial clustering (1). In addition, results from the Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS) support a shared genetic susceptibility of EA and Barrett's esophagus (2). In further analysis of the BEAGESS data, an estimated 25% of the variation in EA risk is due to common genetic variants (1). However, from genome-wide association studies (GWAS) to date, only 7 loci have been identified to be associated with risk of EA or Barrett's esophagus (2, 3), and the effects of the individual genetic variants are small (2, 3). Motivated by studies investigating pleiotropic associations of GWAS-identified variants, some of which work has identified additional risk-associated loci for colorectal, endometrial, and pancreatic cancers (see references in ref. 4), we investigated in BEAGESS whether cancer-GWAS-identified variants could also influence the risk of EA and Barrett's esophagus.

Table 1. SNPs associated with risk of EA, Barrett's esophagus, or EA/Barrett's esophagus, with a nominal *P* value < 0.01 and in the same direction as the GWAS-identified SNPs reported in the NHGRI^a

SNP (major/minor allele)	MAF	Chromosome position	Risk allele	NHGRI catalog ^b		BEAGESS results	
				OR	Cancer site	OR ^c (95% CI)	<i>P</i> (<i>P</i> _{adj} ^d)
SNPs associated with EA							
rs7040024 (A/C)	0.24	chr9: 845516	A	1.70	Testicular	1.16 (1.04–1.30)	0.008 (0.88)
rs4712653 (T/C)	0.45	chr6: 22125964	C	1.40	Neuroblastoma	1.14 (1.03–1.25)	0.008 (0.89)
SNPs associated with Barrett's esophagus							
rs616488 (A/G)	0.34	chr1: 10566215	A	1.10	Breast	1.14 (1.05–1.25)	0.003 (0.59)
rs1270884 (G/A)	0.50	chr12: 114685571	A	1.07	Prostate	1.12 (1.03–1.22)	0.008 (0.88)
SNPs associated with EA/Barrett's esophagus							
rs616488 (A/G)	0.34	chr1: 10566215	A	1.10	Breast	1.13 (1.05–1.23)	0.002 (0.41)
rs1270884 (G/A)	0.50	chr12: 114685571	A	1.07	Prostate	1.12 (1.04–1.21)	0.004 (0.64)
rs2494938 (A/G)	0.48	chr6: 40536128	A	1.15/1.18	Multiple cancers/NCGC ^e	1.11 (1.03–1.20)	0.007 (0.84)
rs527616 (G/C)	0.36	chr18: 24337424	G	1.05	Breast	1.12 (1.03–1.21)	0.008 (0.87)

^aResults from 11 subgroup-specific analyses by smoking status and intensity, BMI, and reflux/heartburn are not presented. *P*_{adj} values for subgroup-specific analyses were further multiplied by 11; the smallest *P*_{adj} from subgroup-specific analyses was 0.22. All *P* for interaction values were above 0.05 after Bonferroni correction [i.e., multiplied by total number of interaction terms examined (387 × 4 = 1,548)].

^bwww.genome.gov/gwastudies.

^cOR for EA, Barrett's esophagus, or EA/Barrett's esophagus per risk allele reported in the NHGRI catalog.

^d*P* values were corrected for multiple testing by calculating "P values adjusted for correlated tests" (6).

^eNon-cardia gastric cancer.

Materials and Methods

Details of the design and methods of BEAGESS have been described elsewhere (2). In brief, this ancillary study included 1,504 EA and 2,384 Barrett's esophagus case patients and 2,163 control participants, all of European descent and for whom genome-wide genotyping and imputation were conducted and phenotype covariate data were available. We identified 407 SNPs that have previously been associated with one or more cancer sites at a *P* value < 5 × 10⁻⁸ in the National Human Genome Research Institute (NHGRI) GWAS catalog as of March 2014 (5). Genotyping was done using the Illumina Human Omni1-Quad platform. Imputation was performed using MaCH and Minimac software and a European reference panel from the 1000 Genomes project (2). This analysis included 387 of the 407 SNPs that had minor allele frequencies (MAF) >1% and passed genotyping and imputation quality control (e.g., imputation *r*² ≥ 0.3; ref. 2). We investigated associations with EA, Barrett's esophagus, and for these conditions combined (EA/Barrett's esophagus). ORs and 95% confidence intervals (CI) were calculated using unconditional logistic regression of case status on additive SNP genotype score, with adjustments for age, sex, and the first four principal components analysis eigenvectors (2). We performed stratum-specific analyses by smoking status (never, former, or current), smoking intensity (never, <30 pack-years, or ≥30 pack-years), BMI (<25, 25–<30, or ≥30 kg/m²), and history of reflux/heartburn (yes, no), and tested for the statistical significance of the interaction (product) term. Some SNPs included in the NHGRI catalog are in linkage disequilibrium with each other. Thus, we calculated "P values adjusted for correlated tests" to account for multiple testing of correlated SNPs (6). The adjusted *P* values (*P*_{adj}) < 0.05 are considered statistically significant. Analyses were conducted using SAS 9.2 (SAS Inc.) and R. All *P* values are two sided.

Results

After correcting for multiple testing, none of the 387 SNPs were associated with risk of EA, Barrett's esophagus, or EA/Barrett's esophagus combined (Table 1 and Supplementary Table S1). No

evidence was seen for effect modification by smoking status or intensity, BMI, or reflux/heartburn history (data not shown).

Discussion

Studies investigating pleiotropic effects of GWAS-identified risk variants have revealed additional risk loci for endometrial, colorectal, and pancreatic cancer, but not for estrogen receptor (ER)-negative breast cancer (ER-positive cancers were not investigated), prostate cancer, or non-Hodgkin lymphoma (4, 7–9). Some studies, including those of non-Hodgkin lymphoma, endometrial cancer, and colorectal cancer, investigated cancer GWAS hits, whereas studies of pancreatic cancer, prostate cancer, and ER-negative breast cancer investigated cancer and noncancer GWAS hits (4, 7–9). Our investigation based on cancer GWAS SNPs is not supportive of shared genetic susceptibility between EA/Barrett's esophagus and other cancer sites. To our knowledge, this is the first study to investigate pleiotropic associations of cancer GWAS loci on risks of EA and Barrett's esophagus. Although our study sample size is moderate, the combined number of EA and Barrett's esophagus cases is larger than that of most previous studies on cancer pleiotropy (4, 7–9). For SNPs with MAF of 0.3 (the average MAF of all tested SNPs), we had 80% statistical power to detect an OR of 1.21 per minor allele for analyses on EA/Barrett's esophagus combined, with a Bonferroni-corrected type I error rate of 5%. Given that nearly one-half (47%) of the NHGRI-cataloged cancer-GWAS SNPs were from studies of more common cancers (Supplementary Table S1), it may be fruitful to repeat this analysis when additional GWAS loci identified from less common cancers become available.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: D.O. Stram, J. Lagergren, L. Bernstein, N.C. Bird, T.L. Vaughan, A.H. Wu

Development of methodology: D.O. Stram, L. Bernstein

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): W. Ye, J. Lagergren, N.J. Shaheen, L.J. Murray,

L.J. Hardie, W.-H. Chow, H.A. Risch, D.A. Corley, D.C. Whiteman, L. Bernstein, N.C. Bird, T.L. Vaughan, A.H. Wu

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E. Lee, D.O. Stram, W.E. Ek, S. MacGregor, P. Gharahkhani, L.J. Murray, H.A. Risch, D.A. Corley, D.M. Levine, A.H. Wu
Writing, review, and/or revision of the manuscript: E. Lee, D.O. Stram, W.E. Ek, L.E. Onstad, S. MacGregor, P. Gharahkhani, W. Ye, J. Lagergren, N.J. Shaheen, L.J. Hardie, M.D. Gammon, W.-H. Chow, H.A. Risch, D.A. Corley, D.M. Levine, D.C. Whiteman, L. Bernstein, N.C. Bird, T.L. Vaughan, A.H. Wu
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L.E. Onstad, M.D. Gammon, T.L. Vaughan
Study supervision: L. Bernstein

Acknowledgments

The authors thank Dr. Yvonne Romero for her contributions to the BEACON consortium. They also thank Drs. Christian Abnet and Matthew Buas for their helpful discussion and suggestions regarding analyses.

References

- Ek WE, Levine DM, D'Amato M, Pedersen NL, Magnusson PK, Bresso F, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. *J Natl Cancer Inst* 2013; 105:1711–8.
- Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. *Nat Genet* 2013;45: 1487–93.
- Palles C, Chegwidden L, Li X, Findlay JM, Farnham G, Castro Giner F, et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. *Gastroenterology* 2015;148:367–78.
- Panagiotou OA, Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, et al. A genome-wide pleiotropy scan for prostate cancer risk. *Eur Urol* 2015;67: 649–57.
- NHGRI GWAS catalog [cited 2014 March 1]. Available from: www.genome.gov/gwastudies.
- Conneely KN, Boehnke M. So many correlated tests, so little time! rapid adjustment of P values for multiple correlated tests. *Am J Hum Genet* 2007;81:1158–68.
- Setiawan VW, Schumacher F, Prescott J, Haessler J, Malinowski J, Wentzensen N, et al. Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. *Carcinogenesis* 2014;35:2068–73.
- Lim U, Kocarnik JM, Bush WS, Matise TC, Caberto C, Park SL, et al. Pleiotropy of cancer susceptibility variants on the risk of non-Hodgkin lymphoma: the PAGE consortium. *PLoS One* 2014;9:e89791.
- Campa D, Barrdahl M, Tsilidis KK, Severi G, Diver WR, Siddiq A, et al. A genome-wide "pleiotropy scan" does not identify new susceptibility loci for estrogen receptor negative breast cancer. *PLoS One* 2014;9:e85955.

Grant Support

This work was primarily funded by a U.S. NIH grant (R01CA136725) to T.L. Vaughan and D.C. Whiteman. E. Lee, D.O. Stram, W.E. Ek, L.E. Onstad, W. Ye, J. Lagergren, N.J. Shaheen, L.J. Murray, L.J. Hardie, M.D. Gammon, H.A. Risch, D.A. Corley, D.M. Levine, D.C. Whiteman, L. Bernstein, N.C. Bird, T.L. Vaughan, and A.H. Wu were supported by R01CA136725. T.L. Vaughan was also supported by grant K05CA124911. D.C. Whiteman was supported by a Research Fellowship from the National Health and Medical Research Council of Australia (NHMRC). S. MacGregor was supported by an Australian Research Council Future Fellowship. Additional funding sources for individual studies included in the BEACON GWAS, and for BEACON investigators, have been acknowledged.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 5, 2015; revised August 15, 2015; accepted August 20, 2015; published OnlineFirst September 12, 2015.